Abstract
510P - Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have